NCT04643561 is a Phase 1, PHASE2 clinical trial of Travelan OTC in Covid19, sponsored by Hadassah Medical Organization.

Who is sponsoring NCT04643561?

NCT04643561 is sponsored by Hadassah Medical Organization.

What drugs are being tested in NCT04643561?

Interventions in NCT04643561: Travelan OTC.

Is NCT04643561 still recruiting?

NCT04643561 is currently status unknown. Last updated 27 November 2020.

Last reviewed 2020-11-27 · How we verify

NCT04643561

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Using Travelan to Boost Immune Response in Vitro to COVID-19

Status unknown Phase 1, PHASE2 Last updated 27 November 2020

What this trial tests

Phase 1, PHASE2 trial testing Travelan OTC in Covid19 in 5 participants. Status unknown.

Timeline

1 November 2020

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Hadassah Medical Organization
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	5
Start date	1 November 2020
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across Israel

Drugs / interventions tested

Travelan OTC

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Hadassah Medical Organization — full company profile →

Who can join

18 and older, male only, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The gut immune system was shown as an effective target for inducing systemic immune signals against viruses. Oral administration of Travelan, an over the counter product which contains hyperimmune bovine colostrum was shown in preclinical studies to augment the anti-viral immune towards several strains of influenza viruses (RNA viruses). This study will evaluate the option that Trevalan may help improve the immune system reaction when introduced to COVID-19 proteins in-vitro. 5 healthy volunteers will receive a treatment regimen of 5 days with Trevalan. Before and after treatment, blood samples will be taken in order to test immune response towards viral proteins of the COVID-19 virus in vitro by measuring the number of T cell clone secreting IFNγ against viral antigens.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical models and a phase I/IIa clinical trial: A method for the prevention and treatment of COVID-19.
Ishay Y, Potruch A, Weksler-Zangen S, Shabat Y, et al · · 2022 · cited 7× · PMID 34596893 · DOI 10.1002/ddr.21890

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Hadassah Medical Organization trials

Trials by the same sponsor.

NCT07430358 — Obstetric Risk Assessment & Cesarean-delivery in Labor Estimation Using Artificial Intelligence · NA · not yet recruiting
NCT07429019 — Intraoperative Bupivacaine Injection to Reduce Acute and Chronic Pain After TVT/TVT-O Surgery. Randomized Double-Blind T · NA · not yet recruiting
NCT07393568 — The Influence of Patient Use of Artificial Intelligence on Doctor-Patient Interaction and Clinical Outcomes in Endometri · not yet recruiting
NCT07333430 — Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma · Phase 1 · recruiting
NCT06762730 — Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Ind · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04643561 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hadassah Medical Organization
Last refreshed: 27 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04643561.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing